{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 59,
  "pageCount": 239,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a visual aid of a standard pain scale to highlight the subjectivity of the clinical trial's primary endpoint.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "screenshot",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/59",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-59",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The potential for bias and patient manipulation is self-evident as the primary endpoint was based on a patient questionnaire called a “Visual Analog Scale” (VAS).",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33a-e64939c9736f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.06,
        "y": 0.37
      },
      "kind": "image",
      "text": "Visual Analog Scale (VAS) diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "952b6d5e-c75b-4a82-ab4c-cab780954c12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "The potential for bias and patient manipulation is self-evident as the primary endpoint was based on a patient questionnaire called a “Visual Analog Scale” (VAS). Patients needed to report VAS pain score reductions of 50% to be considered a responder.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eefc7e0-ca53-47ec-8389-83ad50288cf7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.6,
        "y": 0.37
      },
      "kind": "quote",
      "text": "“This was all nebulous because pain management and neuromodulation are subjective... The problem is it’s very subjective... There’s a major psychological component, which is why a psychiatric evaluation is required for permanent implant.” – Former Nevro regional sales director",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0059d302-cd01-45b7-b041-67e43a5407be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“This was all nebulous because pain management and neuromodulation are subjective. The primary endpoint in the Nevro trials was VAS reductions. The problem is it’s very subjective. Patients’ pain and location can change hour to hour and day to day. It’s such a tough specialty because it’s so nebulous. If the diagnosis is an ACL tear, the surgeon can confirm it with imaging. The problem with chronic pain is that it’s not one specific modality. There’s a major psychological component, which is why a psychiatric evaluation is required for permanent implant.” — Former Nevro regional sales director, head of a large multi-state territory",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33a-e9017be9c492",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: http://www.ericlinmd.com/back-vas-form.php; expert consultation calls",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cab1035-7057-4a88-aca6-7db50a702df6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "3. Trial investigators, KOL's, and ex-employees painted the SENZA pivotal study as a fraud",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1895527c-2615-482a-ac5a-4a3a936e7f80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10c35c84-29a6-41b8-9539-92e7cd16cd50",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "9e271d9f-9c93-44de-bf37-89e5352bd2ab",
      "evidence": "The slide explicitly frames the clinical trial as a 'fraud' based on subjective methodology.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 60,
      "from": 50,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d046baf7-54ed-409a-b6fc-7a2d900bc1ce",
      "evidence": "The deck emphasizes the risks of not addressing Nevro's problems",
      "position": 1,
      "objective": "Highlight the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}